Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Very Slow Chiral Inversion of Clopidogrel in Rats: A Pharmacokinetic and Mechanistic Investigation

Marianne Reist, Marieke Roy-de Vos, Jean-Pierre Montseny, Joachim M. Mayer, Pierre-Alain Carrupt, Yves Berger and Bernard Testa
Drug Metabolism and Disposition December 2000, 28 (12) 1405-1410;
Marianne Reist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marieke Roy-de Vos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Montseny
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joachim M. Mayer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre-Alain Carrupt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Berger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Testa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Clopidogrel hydrogen sulfate, a thienopyridine derivative, is an ADP receptor antagonist that inhibits platelet aggregation. Clopidogrel is an enantiopure carboxylic ester of S-configuration. The R-enantiomer is devoid of antithrombotic activity and can provoke convulsions at high doses in animals. During preclinical safety evaluation, the possible chiral inversion of clopidogrel has, therefore, been investigated in vivo after repeated oral administration of different dose levels of clopidogrel to male and female rats. Due to rapid metabolism in the liver and low plasma levels of unchanged drug, possible chiral inversion was assessed by monitoring the plasma concentrations of the carboxylic acid metabolites, i.e., the (S)- and (R)-acid, by means of a stereoselective assay. The production of 4 to 8% of (R)-acid was observed. This could be the result of chiral inversion of either clopidogrel or its main metabolite, the (S)-acid. Thus, the possibility of nonenzymatic and enzymatic inversion of clopidogrel and its carboxylic acid metabolite was studied in vitro by chiral HPLC and 1H NMR. Nonenzymatic chiral inversion of clopidogrel at 37°C in 0.1 M phosphate buffers could be observed but was found to be slow, with estimated half-lives of 7 to 12 days, depending on the pH. The (S)-acid was configurationally fully stable up to 45 days in phosphate buffers. Neither clopidogrel nor its carboxylic acid metabolites were subject to enzymatic chiral inversion in isolated rat hepatocyte suspensions. We conclude that the nonenzymatic inversion of clopidogrel accounts for the 4 to 8% of chiral inversion seen in vivo in the rat.

Clopidogrel hydrogen sulfate, methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-acetate hydrogen sulfate, is a thienopyridine derivative chemically related to ticlopidine (see Fig. 1). Clopidogrel (Plavix/Iscover) is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease (Plavix/Iscover, data on file). Clopidogrel is inactive in vitro and the active metabolite of the drug inhibits ADP-induced platelet aggregation by direct inhibition of ADP binding to its receptor and therefore by inhibition of the subsequent ADP-mediated activation of the glycoprotein GIIb/IIIa complex (Gachet et al., 1992; Humbert et al., 1998).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Potential reactions of chiral inversion (a) and hydrolysis (b) of clopidogrel investigated in this study.

Clopidogrel is a chiral drug with S-configuration. It is rapidly absorbed and undergoes extensive metabolism and metabolic activation in animals and humans. Hydrolysis of the ester function by carboxylesterase leads to the carboxylic acid derivative withS-configuration (see Fig. 1), which is the main circulating metabolite (about 85% of the circulating drug-related compounds in plasma). Furthermore, clopidogrel is oxidized on the thiophene ring by cytochrome P450-1A in the liver (Herbert et al., 1993; Plavix/Iscover, data on file). Experiments performed in vivo in the rat showed that clopidogrel bioactivation occurred in the liver via the oxidative pathway (Savi et al., 1992, 1994).

The R-enantiomer is devoid of antithrombotic activity and can evoke convulsions at high doses in animals (Gardell, 1993). During safety evaluation in animals, special attention was, therefore, required due to a possible chiral inversion of clopidogrel. Figure1 illustrates the potential reactions of chiral inversion and hydrolysis considered in this study. First, chiral inversion of clopidogrel has been investigated in vivo after repeated oral administration of different dose levels of clopidogrel hydrogen sulfate to male and female rats. Because of the low plasma levels of unchanged drug (Herbert et al., 1993), a possible chiral inversion of clopidogrel was assessed by monitoring the plasma concentrations of its carboxylic acid derivatives with S- andR-configuration, using a stereoselective assay. To get further insights, the nonenzymatic (i.e., chemical) inversion of clopidogrel was studied by chiral HPLC and by 1H NMR [1H/2H substitution according to Kawazoe and Ohnishi (1964), Testa (1973), Reist et al. (1995, 1996)], and the effects of pH, buffer concentration, ionic strength, and polarity of the solvent were examined. The configurational stability of the (S)-acid was verified by1H NMR, although its nonenzymatic inversion is highly improbable, because a free carboxy group is known to strongly increase the configurational stability of chiral carbon atoms of the type R"R′RC-H (Testa et al., 1993; Reist et al., 1997). The enzymatic inversion of clopidogrel and its carboxylic acid derivatives was investigated in isolated rat hepatocyte suspensions. A number of anti-inflammatory 2-arylpropionic acids are well known to invert configuration via their CoA1thioester conjugate (Knihinicki et al., 1989; Mayer, 1990). Thus, the possibility that the (S)- and/or (R)-acid metabolites of clopidogrel invert via a similar mechanism was investigated.

Materials and Methods

Chemicals.

Clopidogrel hydrogen sulfate, the hydrogen sulfate of itsR-enantiomer, and the hydrochlorides of their carboxylic acid derivatives [(S)-acid and (R)-acid] were supplied by Sanofi Recherche (Montpellier, France). Their optical purities were 98.9, 98.2, 94.3, and 95.2%, respectively. α-(2-Methylphenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-acetic acid was also supplied by Sanofi Recherche. (S)-(+)-Ibuprofen was generously donated by the Boots Co. Ltd. (Nottingham, England). BSA (fraction V) was purchased from Fluka Chemie AG (Buchs, Switzerland). Collagenase (Clostridium histolyticum type IV), EGTA, (S)-(−)-α-(1-naphthyl)ethylamine (enantiomeric excess >98%), 1-hydroxybenzotriazole (HOBT), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC) were obtained from Sigma Chemical Co. (St. Louis, MO). The deuterated solvents were purchased from Armar (Döttingen, Switzerland), and their isotopic purities were: D2O 99.8 atom%D, DMSO-d6 99.8 atom%D, and CD3CN 99.8 atom%D. All other chemicals were of analytical grade and used without further purification.

In Vivo Chiral Inversion in Rats.

Animals

This study was conducted in compliance with the principles of Good Laboratory Practice. At the beginning of the treatment period, Crl CD (SD) BR rats (Charles River, Saint-Aubin-les-Elbeuf, France) were approximately 6 weeks old and had mean body weights of 192 g and 159 g for males and females, respectively. During the study, the animals were housed in suspended wire-mesh cages (43.0 × 21.5 × 18.0 cm), and each cage contained two rats of the same sex and group. The animal rooms had a temperature range of 19–23°C, a relative humidity range of 30 to 70%, and a light/dark cycle of 12 h. Animals had free access to diet (A04 C diet, U.A.R., Villemoisson-sur-Orge, France) and to tap water filtered with a 0.22-μm filter (Millipore S.A., Vélizy, France).

Study design.

After clinical examination to ensure animals were in good health, 96 male and 96 female rats were assigned to four experimental groups receiving different levels of clopidogrel hydrogen sulfate (10, 35, 100, and 160 mg/kg/day). The drug was administered in the diet during 4 weeks. The concentration of clopidogrel hydrogen sulfate in the diet was modified every week according to body weight and food consumption data, to maintain the adequate dose levels for each group. To determine the exposure at steady-state after 4 weeks, blood samples were collected every 3 h from day 27 at 7:00 PM to day 28 at 7:00 PM, i.e., on day 27 at 7:00 and 10:00 PM, and on day 28 at 1:00, 4:00, 7:00, and 10:00 AM and at 1:00, 4:00, and 7:00 PM. AUC0–24 h values were calculated from 7:00 PM on day 27 to 7:00 PM on day 28. This 24-h period corresponded to a light/dark cycle (12 h/12 h) in animal rooms. At each sampling time, blood samples were collected from four individual males and four individual females per experimental group. To reduce the total number of animals, for half of the rats per group, two blood samples were withdrawn from the same animal with an interval period of 12 h. Blood was collected in tubes containing lithium heparin as an anticoagulant, from the orbital sinus of the animals under slight ether anesthesia. After centrifugation, plasma samples were stored at −20°C until assayed for (S)-acid and (R)-acid.

Analytical method.

After addition of α-(2-methylphenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-acetic acid as internal standard (5 μg), the stereoselective analysis of the (S)-acid and (R)-acid was carried out as follows. The extraction and derivatization procedures were modifications of the method of Hutt et al. (1986). Briefly, to an aliquot of plasma (0.25 ml) acetate buffer, pH 5 (0.75 ml), and acetonitrile (0.25 ml) were added. This solution was placed on top of an Extrelut-1 column (Merck, Darmstadt, Germany). A first elution with hexane (5 ml) was discarded, and analytes were eluted with CH2Cl2 (5 ml). After evaporation of the solvent, the dry residue was reconstituted in CH2Cl2 (1 ml) and derivatized with(S)-(−)-α-(1-naphthyl)ethylamine (0.1 ml of a 6 mg/ml solution in CH2Cl2) in the presence of HOBT (0.1 ml of a 1.5 mg/ml solution in CH2Cl2) and EDAC (0.1 ml of a 1.5 mg/ml solution in CH2Cl2). After a 16-h incubation at room temperature, water (4 ml) and hexane (3 ml) were added. The two phases were separated, and the organic phase reduced to dryness at room temperature under a stream of nitrogen. The dry residue was dissolved in the HPLC mobile phase (20 μl).

The 1-naphthylethylamide derivatives of (S)- and (R)-acid were separated on a Hypersil ODS 5 μm stationary phase (250 mm × 4 mm; Lichrocart, Merck, Darmstadt, Germany). The mobile phase consisted of acetonitrile/triethylammonium acetate buffer, pH 3.3, 0.01 M (55:45, v/v) delivered at a flow rate of 1.25 ml/min. Spectrofluorimetric detection was performed at excitation and emission wavelengths of 280 and 330 nm, respectively. Linearity over the standard range [0.60–40 mg/l for (S)-acid and 0.06–4 mg/l for (R)-acid] was shown. The interday coefficients of variation for (S)-acid at concentrations of 0.60, 6.0. and 40 mg/l were 4.3, 6.0 and 4.6%, and those for (R)-acid at concentrations of 0.06, 0.60 and 4.0 mg/l were 8.0, 8.4, and 4.3%. The retention times of the amides of the (S)- and (R)-acid were about 26 and 32 min, respectively.

Data analysis.

Concentrations of (S)- and (R)-acid were expressed as unsalified compounds. On days 27 and 28, population estimates of AUC0–24 h and their standard errors were calculated for each dose level by sex combination using the linear trapezoidal rule on average concentration at each sampling time (Yeh, 1990). Considering the composite design adopted for blood samplings, the terminology “population estimates” has been used. For all estimates, 95% confidence intervals were calculated from the standard error of the estimate, and degrees of freedom were determined using the Satterthwaite procedure.

Analyses were performed using the GLM and IML procedures in the SAS statistical software package (version 6.09) (SAS Institute Inc., Cary, NC) and macro DSTRCT3 of the biostatistics program.

Nonenzymatic Chiral Inversion and Hydrolysis Monitored by HPLC.

In aqueous solutions at physiological pH, clopidogrel hydrogen sulfate is very slightly soluble (<0.001 mg/ml), and a cosolvent (methanol) had to be used to investigate its nonenzymatic chiral inversion and hydrolysis by HPLC.

Three mixtures of methanol with phosphate buffer pH 7.4 (0.2 M, ionic strength 0.52), in the proportions 1:1, 2:3, and 1:2 (v/v) were prepared to assess the influence of methanol concentration. The influence of pH was investigated by measuring reaction rates in 1:1 (v/v) mixtures of methanol and phosphate buffers (0.1 M, ionic strength 0.3) of four different pH values, pH 3.0, 5.6, 7.4, and 9.0. To study the influence of buffer concentration, 1:1 (v/v) mixtures of methanol and phosphate buffers (pH constant at 7.4, ionic strength 0.78) of three different concentrations (0.1, 0.2, and 0.3 M) were prepared. Mixtures (1:1, v/v) of methanol and phosphate buffers (pH 7.4, 0.2 M) of three different ionic strengths (0.52, 0.6, 0.78) were prepared to investigate the influence of ionic strength.

Clopidogrel hydrogen sulfate (30 mg, 7.738 × 10−5 M) was dissolved in 100 ml of the solvent mixtures described above. Each solution was placed in a 100-ml bottle with a crown cap and kept in a rotating water bath at 37 ± 0.2°C. Kinetic studies were performed by repeated sampling of 0.2-ml reaction mixture followed by HPLC analysis over a time interval of 78 days.

To observe a possible esterification of the (S)-acid, 1:1 (v/v) mixtures of methanol and phosphate buffers (0.1 M, ionic strength 0.3) of pH 7.4 and pH 9.0 were prepared. The (S)-acid hydrochloride (30 mg, 8.309 × 10−5) was dissolved in 100 ml of solvent mixture, and the solutions were handled like the clopidogrel solutions. Analyses were performed over a time interval of 42 days.

Analytical methods.

To monitor chiral inversion, clopidogrel and its enantiomer were separated on a Nucleodex β-PM column 150 × 4.6 mm (Macherey-Nagel, Düren, Germany), using the mobile phase methanol/triethylammonium acetate buffer, pH 4.0, 0.1% (65:35, v/v), a flow rate of 0.7 ml/min, and UV detection at 230 nm. The retention times of clopidogrel and its enantiomer were 19.1 and 22.1 min, and the detection limits 2 and 2.5 mg/l, respectively.

To monitor either the hydrolysis of clopidogrel or the esterification of the (S)-acid, a nonstereospecific assay method was used. Clopidogrel plus its enantiomer and the two carboxylic acid derivatives [(S)-acid plus (R)-acid] were separated on a Supelcosil LC-ABZ column 150 × 4.6 mm (Supelco, Gland, Switzerland) using the mobile phase methanol/phosphate buffer, pH 7.5, 0.01 M (70:30, v/v) plus decylamine 0.01 M, a flow rate of 0.8 ml/min, and UV detection at 230 nm. The retention times of the acids and esters were 4.5 and 9.2 min, and the detection limits were approximately 1 and 2.5 mg/l, respectively.

Data analysis.

The apparent pseudo first order rate constants of chiral inversion of clopidogrel (kS-to-R) were calculated according to eq. 1:ln[Clopidogrel]t−[(R)­enantiomer]t[Clopidogrel]t+[(R)­enantiomer]t×100=−2kS­to­R×t Equation 1where [Clopidogrel]t is the concentration of clopidogrel at time t and [(R)-enantiomer]t the concentration of the increasing antipode of clopidogrel at time t. The apparent pseudo first order rate constants of hydrolysis (khyd) were calculated as follows:ln([Clopidogrel]t+[(R)­enantiomer]t)=−khyd×t Equation 2

Nonenzymatic Chiral Inversion Monitored by 1H NMR.

The configurational stability of clopidogrel and its carboxylic acid derivative, the (S)-acid, was monitored by1H NMR (1H/2H substitution). The method takes advantage of the fact that the inversion of chiral centers of the type R"R′RC-H and proton-deuterium exchange share a common mechanism (Kawazoe and Ohnishi, 1964; Testa, 1973; Reist et al., 1995,1996). Briefly, when a compound having a chirally labile C-H group is dissolved in D2O, the proton is irreversibly replaced by a deuterium, and deuteration can be followed by integrating the signal of the exchanging proton. The 1H NMR spectra and integrals were recorded on a Varian VXR-200 NMR spectrometer operating at 200 MHz (Varian Associates Inc., Palo Alto, CA).

Clopidogrel.

For clopidogrel, the four media investigated consisted of D2O (pD 1.7), DMSO/D2O (2:1), CD3CN/D2O (1:1), and DMSO/phosphate buffer pD 7.4, 0.2 M (2:1). Clopidogrel hydrogen sulfate (20 mg, 5.159 × 10−5 M) was dissolved in 1 ml of solvent. Each such solution was placed in a NMR tube and kept in a water bath at 37 ± 0.2°C. At various time intervals up to 116 days, 1H NMR spectra and integrals were recorded at 37°C.

(S)-Acid.

20 mg (5.539 × 10−5 M) of (S)-acid hydrochloride were dissolved in 1 ml of phosphate buffer pD 7.4, 0.2 M, or in 1 ml of D2O adjusted to a pD of 12 with NaOD. Each solution was placed in a NMR tube and kept at 50 ± 0.2°C in a water bath. At various time intervals up to 45 days 1H NMR spectra and integrals were recorded at 50°C.

Data analysis.

For clopidogrel, the sum of the rate constants of deuteration and hydrolysis (kdeut +khyd) was calculated according to eq. 3:ln(At/Bt)=−(kdeut+khyd)×t Equation 3where At is the integral of the exchanging proton coupled to the chiral center of clopidogrel (singlet between 5 and 6 ppm) at time t, andBt is the integral of the unexchangeable reference protons at time t. The apparent pseudo first order rate constant of hydrolysis was calculated using eq. 4:ln(Ct/Bt)=−khyd×t Equation 4where Ct is the integral of the methanol singlet around 3.3 ppm at time t, andBt is the integral of the unexchangeable reference protons at time t. Knowing the sum of the rate constants of deuteration and hydrolysis (kdeut + khyd) and that of hydrolysis khyd, the rate constant of deuteration kdeut can easily be calculated.

For the (S)-acid, the rate constant of deuteration (kdeut) was obtained by plotting the natural logarithm of the decreasing integral of the signal of the proton coupled to the chiral center (singlet around 5.3 ppm) as a function of time.

Enzymatic Chiral Inversion and Hydrolysis in Rat Hepatocyte Suspensions.

Animals

The male Sprague-Dawley rats (200–300 g, BRL, Füllinsdorf, Switzerland) used to provide hepatocytes were kept in an air-conditioned environment (21.5°C, 50% humidity), on a normal 12-h light/dark cycle. The animals had free access to water and food (Nafag Futter, Nafag, Gossau, Switzerland) until the morning of sacrifice.

Preparation of rat hepatocyte suspensions.

Rat hepatocytes were isolated by a two-step collagenase (Clostridium histolyticum type IV) perfusion of the liver as reported previously (Seglen, 1975; Roy-de Vos et al., 1996). The cells (5 × 105 cells/ml) were resuspended in Hanks' buffer containing 0.5% BSA (fraction V) (Hanks and Wallace, 1949).

Incubation conditions.

After addition of the substance under investigation (either clopidogrel, the (S)-acid, or the (R)-acid), incubations were carried out for 4 h at 37°C under agitation in an air/CO2 (95:5; v/v) atmosphere (CO2 of medicinal grade; Carbagaz SA, Lausanne, Switzerland). Cell viability, determined by Trypan Blue exclusion, was routinely greater than 85%.

Every 30 min, 5 ml of cell suspension was removed. One-half of each sample was treated for the stereoselective analysis of (S)-acid and (R)-acid to detect a possible chiral inversion, and the other half for the nonstereoselective analysis of clopidogrel and its carboxylic acid derivatives to assess hydrolysis. The cells were separated by centrifugation, and the supernatant was collected. For the stereoselective analysis of the acid derivatives, an internal standard, (S)-ibuprofen (60 μg/sample), was added to the supernatant and all samples were freeze-dried.

Analytical methods.

For the nonstereoselective analysis of clopidogrel and its acids, the freeze-dried residue from a 2.5-ml sample was dissolved in 1 ml of methanol, mixed thoroughly for 10 s and centrifuged. Twenty microliters of the supernatant were injected for HPLC analysis on a Supelcosil LC-ABZ column as described above (under Nonenzymatic Chiral Inversion and Hydrolysis Monitored by HPLC). Because the sample preparation was very simple, the addition of an internal standard proved unnecessary. The lowest concentration detected in the incubation medium was approximately 1 mg/l for the acids and 3 mg/l for the esters.

The stereoselective analysis of the (S)-acid and (R)-acid was carried out as follows. The extraction and derivatization procedures were modifications of the methods of Hutt et al. (1986). Briefly, acetate buffer pH 5 (0.7 ml) and acetonitrile (0.3 ml) were successively added to the freeze-dried residue to precipitate albumin, and the samples were extracted with dichloromethane. The organic phases were evaporated to dryness and derivatized with (S)-(−)-α-(1-naphthyl)ethylamine (0.2 ml of a 1 mg/ml solution in CH2Cl2) in the presence of HOBT (0.1 ml of a 1 mg/ml solution in CH2Cl2) and EDAC (0.2 ml of a 1 mg/ml solution in CH2Cl2) to form the diastereomeric amides of the (S)- and (R)-acid. The residue was dissolved in 0.3 ml of water and analyzed by HPLC on a 5 μm Nucleosil 50 column (250 × 4 mm, Knauer, Berlin, Germany). The mobile phase consisted of hexane/ethyl acetate (85:15, v/v) delivered at a flow rate of 1.0 ml/min. The naphthylethylamides of the (R)- and (S)-acid and of the internal standard (S)-ibuprofen eluted at 7.6, 8.5, and 9.4 min, respectively. The lowest concentration of each enantiomer detected in the incubation medium was 0.2 mg/l.

Data analysis.

A two-compartmental model with elimination from both compartments was used to investigate the hydrolysis of clopidogrel in rat hepatocyte suspensions, with kAB designating the first order rate constant of hydrolysis of clopidogrel, andkA and kB the first-order rate constants of the nonhydrolytic elimination of clopidogrel and the (S)-acid, respectively. Data analysis was carried out with a nonlinear regression program (Siphar, Simed S.A., Créteil, France).

Results

In Vivo Chiral Inversion in Rats.

Clopidogrel hydrogen sulfate administered orally (in the diet) to rats at dose levels of 10, 35, 100, and 160 mg/kg/day over a 4-week period was well tolerated by all animals, and no clinical signs of adverse reaction to the treatment were observed. From food consumption, the achieved dosages were in good agreement with the nominal dosage for each sex and at all dose levels, throughout the study. Overall mean values were 10.2, 35.2, 99.4, and 160.7 mg/kg/day in males, and 9.8, 33.6, 96.7, and 154.5 mg/kg/day in females.

Due to low plasma levels of unchanged drug (Savi et al., 1992, 1994), its carboxylic acid derivatives have been used as surrogate marker for the possible chiral inversion of clopidogrel. Values forCmax (maximal plasma concentration) and AUC0–24 h (total area under the plasma drug concentration-time curve for 24 h) of both acid enantiomers determined after 4 weeks are given in Table1. From mean AUC values, the contribution of the (R)-acid to the total acid exposure was 6.4, 5.8, and 4.9% in male rats at 35, 100, and 160 mg/kg dose levels, respectively, and 7.6, 4.7, and 3.7% in female rats at 35, 100, and 160 mg/kg dose levels, respectively. (R)-Acid contribution was constant over the dosing interval. Thus, 4 to 8% of (R)-acid could be detected in the plasma of all animals, independent of sex.

View this table:
  • View inline
  • View popup
Table 1

Systemic pharmacokinetics of the (S)-acid and (R)-acid determined from day 27 7:00 PM to day 28 7:00 PM after repeated oral (admixture with diet) administration of clopidogrel hydrogen sulfate to rats

Nonenzymatic Chiral Inversion and Hydrolysis Monitored by HPLC.

Estimated half-lives of nonenzymatic chiral inversion and hydrolysis of clopidogrel in the investigated media were between 3.5 and 8.5 weeks, and 3 and 36 months, respectively. The influences of methanol concentration, pH, phosphate concentration, and ionic strength on the rate constants of chiral inversion and hydrolysis are shown in Table2. The rates of inversion and hydrolysis decreased with increasing methanol concentration and were pH-dependent. The chiral inversion was slower in acidic solutions than in neutral or basic media, and the hydrolysis showed a minimum at a pH around 5 and increased in acidic and in alkaline media. The rates of both reactions were proportional to the phosphate concentration.

View this table:
  • View inline
  • View popup
Table 2

Influence of methanol concentration, pH, phosphate concentration, and ionic strength on the rate constants of chiral inversion kS-to-R and hydrolysis khyd of clopidogrel at 37°C

By extrapolating the results obtained to 0% methanol concentration, rate constants of chiral inversion and hydrolysis of clopidogrel at 37°C in phosphate buffers of various pH values were estimated. The estimated rate constants and t90 values, time for 10% hydrolysis or chiral inversion, are summarized in Table3.

View this table:
  • View inline
  • View popup
Table 3

Apparent rate constants and t90 values of chiral inversion and hydrolysis of clopidogrel at 0% methanol and 37°C, in phosphate buffers 0.1 M, ionic strength 0.3

No esterification of the (S)-acid in the investigated 1:1 (v/v) mixtures of methanol and phosphate buffers of pH 7.4 and 9.0 was observed up to 42 days.

Nonenzymatic Chiral Inversion Monitored by 1H NMR.

1H NMR has previously been shown to be a suitable tool to assay inversion of chiral centers of the type R"R′RC-H (Kawazoe and Ohnishi, 1964; Testa, 1973; Reist et al., 1995, 1996). The rates of deuteration of clopidogrel in different solvents at 37°C are shown in Table 4. Deuteration and, therefore, chiral inversion of clopidogrel in all solvents were found to be low. In fact, the estimated half-lives of deuteration were between 1 and 8 months.

View this table:
  • View inline
  • View popup
Table 4

Deuteration of clopidogrel at 37°C in different solvents, as monitored by 1H NMR

The investigation of the deuteration (i.e., chiral inversion) of the (S)-acid of clopidogrel showed no disappearance of the signal of the proton coupled to its chiral center (singlet around 5.3 ppm). Because the detection limit of the method by1H NMR used was 0.1 mg/ml, it can be deduced that in 45 days less than 0.5% inversion occurred. Hence, the configuration of the (S)-acid can be considered as stable up to 45 days in all media studied.

Enzymatic Chiral Inversion and Hydrolysis in Rat Hepatocyte Suspensions.

Incubations of clopidogrel

Isolated rat hepatocytes were incubated with different concentrations of clopidogrel (25, 50, and 100 mg/l) and the formation of the (S)- and (R)-acid was monitored. Only the (S)-acid, the carboxylic acid derivative with the same configuration as clopidogrel, was detected at all concentrations investigated. The concentration of the (S)-acid increased with time and reached maximal levels of 7 to 15 mg/l, depending on the initial concentration of clopidogrel. Because the detection limit of each enantiomer in the incubation medium was 0.2 mg/l, it can be deduced that there was less than 1 to 2% of chiral inversion of clopidogrel occurring in rat hepatocyte suspensions.

The hydrolysis of clopidogrel in rat hepatocyte suspensions is illustrated in Fig. 2, showing the rapid decrease of clopidogrel (25 mg/l) with a simultaneous increase in concentration of the (S)-acid. The rate of hydrolysis of clopidogrel (kAB = 0.52 ± 0.028 h−1) is slower than its nonhydrolysis elimination (kA = 0.82 ± 0.049 h−1). In rat hepatocyte suspensions, approximately 39% of the initial concentration of clopidogrel was hydrolyzed to its carboxylic acid metabolite withS-configuration. It can further be noted that the time-concentration profile of (S)-acid after incubation of 25 mg/l of clopidogrel, determined with the nonstereoselective method, was identical to that obtained with the stereoselective method.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Incubations of clopidogrel hydrogen sulfate (25 mg/l) in rat hepatocyte suspensions (5 × 105cells/ml): elimination of clopidogrel and simultaneous formation of its carboxylic acid derivative.

Mean of four incubations ± standard deviation. Solid line, clopidogrel; dashed line, (S)-acid.

Incubations of the (S)-acid and(R)-acid.

At incubations of either the (S)-acid or (R)-acid (10 mg/l) no formation of the antipodes could be detected during the 4 h of incubation, indicating a lack of enzymatic inversion of (S)-acid to (R)-acid or vice versa. The elimination of the acids was of first order, and no significant difference in the rates of elimination of the enantiomers was observed. Indeed, the elimination rate constants were 0.25 ± 0.010 and 0.26 ± 0.015 h−1 for the (S)- and (R)-acid, respectively.

Discussion

Daily oral administration of different dose levels of clopidogrel (10–160 mg/kg/day) over a 4-week period to male and female rats resulted in production of 4 to 8% of the (R)-acid, the carboxylic acid derivative with configuration opposite to that of clopidogrel. Indeed, plasma levels of the (S)-acid were 12- to 25-fold higher than those of (R)-acid. Despite the fact that, at the 100 mg/kg/day dose level, the (R)-and (S)-acid AUC values were significantly greater for males than for females, a finding that deserves confirmation, the contribution of (R)-acid was independent of sex and constant over the dosing interval. This observed appearance of a small percentage of (R)-acid in the plasma could be the result of nonenzymatic or enzymatic chiral inversion of either clopidogrel or its main metabolite, the (S)-acid. To address this question further, investigations in vitro on the mechanism of chiral inversion of clopidogrel and its carboxylic acid derivatives were performed.

The nonenzymatic chiral inversion and hydrolysis of clopidogrel in all investigated media were found to be slow. Both rates of reaction were pH-dependent and decreased with increasing methanol concentration. These findings are in good agreement with the fact that inversions of chiral centers of the type R"R′RC-H and hydrolyses are in general acid- and/or base-catalyzed processes (Isaacs, 1987a; Reist et al., 1995) and thus expected to be pH-dependent. Also, both processes are thought to proceed faster in aqueous than in methanolic solutions (Isaacs, 1987b). Both reaction rates were also found to be proportional to the phosphate concentration. With a 3-fold increase in phosphate concentration, the rate constant of chiral inversion increased 1.1-fold and that of hydrolysis 1.3-fold. Hence, chiral inversion and hydrolysis of clopidogrel followed a very weak general-base catalysis, in contrast to the marked general-base catalysis seen in cases of ready racemization (Reist et al., 1995, 1996). Because the rates of chiral inversion and hydrolysis decreased only very slowly with increasing ionic strength, it can be deduced that phosphate concentration and ionic strength have only a marginal influence on the chiral inversion and hydrolysis of clopidogrel.

Although the nonenzymatic chiral inversion of the (S)-acid is improbable, due to the fact that a carboxy group is known to stabilize chiral carbon atoms of the type R"R′RC-H (Testa et al., 1993;Reist et al., 1997), its configurational stability was investigated by1H NMR. 1H NMR has previously been shown to be a suitable tool to assay inversion of chiral centers of the type R"R′RC-H (Kawazoe and Ohnishi, 1964; Testa, 1973; Reist et al., 1995, 1996). The method takes advantage of the fact that the inversion of such chiral centers and proton-deuterium exchange share a common mechanism. As expected, no deuteration was observed and the configuration of (S)-acid was found to be stable up to 45 days in all media studied.

Enzymatic chiral inversion of clopidogrel and its carboxylic acid derivatives was investigated in rat hepatocyte suspensions. In contrast to nonenzymatic chiral inversion, which is of ubiquitous occurrence, only a limited variety of enzymatic reactions are known to interconvert stereoisomers (Testa et al., 1993). One of them is the enzymatic chiral inversion of anti-inflammatory 2-arylpropionic acids (Knihinicki et al., 1989; Mayer, 1990). The inactive (R)-enantiomer of ibuprofen and a few analogues are enantioselectively conjugated with coenzyme A to yield the (R)-acyl-CoA thioester. This conjugate is then epimerized to a mixture of the (S)- and (R)-acyl-CoA, followed by hydrolysis to yield a profen enriched in the (S)-form. Because this reaction was observed in isolated rat hepatocyte suspensions (Mayer et al., 1994; Roy-de Vos et al., 1996), the same investigation medium was chosen to study the possibility that the clopidogrel acids invert via a similar reaction mechanism. However, our results show that neither clopidogrel nor its carboxylic acid derivatives were subject to enzymatic chiral inversion in rat hepatocyte suspensions. Indeed, when clopidogrel was incubated, only the (S)-acid was formed, and when either (S)- or (R)-acid were incubated, no formation of the corresponding antipode could be observed.

In summary, the apparent rate constants of nonenzymatic chiral inversion of clopidogrel at 37°C in phosphate buffers, the absence of nonenzymatic chiral inversion of (S)-acid, and the lack of enzymatic chiral inversion of clopidogrel and its carboxylic acid derivatives in rat hepatocyte suspensions seem to be in good agreement with the 4 to 8% of chiral inversion seen in rats. From our results we deduce that nonenzymatic inversion of the ester, even if slow in the investigated media, accounts for the 4 to 8% of chiral inversion occurring in vivo in rats. To confirm our hypothesis, additional experiments conducted in protein solution and plasma could be of interest. Indeed, endogenous bases such as proteins, amines and amino acids, thiolate groups, and carbonate can be expected to contribute to an acceleration of the nonenzymatic chiral inversion (Reist et al., 1995). In humans, plasma levels of the (R)-acid were consistently below the limit of detection (Necciari et al., 1996) after single oral administration of clopidogrel doses up to 150 mg.

In conclusion, the nonenzymatic inversion of clopidogrel demonstrated in vivo in rats during preclinical development has no clinical significance.

Acknowledgments

We are grateful to Dr. Christine Fabreguettes (Center International de Toxicologie, Evreux, France) for conducting the in-life phase in rats and to Dr. David Young (Sanofi Research Division, Alnwick, UK) for the statistical analysis of pharmacokinetic data.

Footnotes

  • Send reprint requests to: Bernard Testa, Université de Lausanne, Institut de Chimie Thérapeutique, BEP, CH-1015 Lausanne, Switzerland. E-mail:bernard.testa{at}ict.unil.ch

  • Abbreviations used are::
    CoA
    coenzyme A
    AUC
    area under the concentration versus time curve
    Cmax
    maximum concentration
    EDAC
    1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
    HOBT
    1-hydroxybenzotriazole
    DMSO
    dimethyl sulfoxide
    (R)-acid
    carboxylic acid derivative of clopidogrel withR-configuration
    (S)-acid
    carboxylic acid derivative of clopidogrel with S-configuration
    atom%D
    percentage deuterium relative to total hydrogen in a given amount of compound
    • Received May 16, 2000.
    • Accepted September 11, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics

References

    1. CAPRIE Steering Committee
    (1996) A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 348:1329–1339.
    OpenUrlCrossRefPubMed
  1. ↵
    1. Gachet C,
    2. Savi P,
    3. Ohlmann P,
    4. Maffrand JP,
    5. Jakobs KH,
    6. Cazenave JP
    (1992) ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes: An effect selectively blocked by the thienopyridine clopidogrel. Thromb Haemostasis 68:79–83.
    OpenUrlPubMed
  2. ↵
    1. Gardell SJ
    (1993) Ticlopidine and clopidogrel: Antithrombotic agents that block ADP-mediated platelet activation. Perspect Drug Discov Des 1:521–526.
    OpenUrl
  3. ↵
    1. Hanks JH,
    2. Wallace RE
    (1949) Relation of oxygen and temperature in the preservation of tissues by refrigeration. Proc Soc Exp Biol Med 71:196–206.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Herbert JM,
    2. Frehel D,
    3. Vallée E,
    4. Kieffer G,
    5. Gouy D,
    6. Berger Y,
    7. Necciari J,
    8. Defreyn G,
    9. Maffrand JP
    (1993) Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 11:180–198.
    OpenUrlCrossRef
  5. ↵
    1. Humbert M,
    2. Nurden P,
    3. Bihour C,
    4. Pasquet JM,
    5. Winckler J,
    6. Heilmann E,
    7. Savi P,
    8. Herbert JM,
    9. Kunicki TJ,
    10. Nurden AT
    (1998) Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherent defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol 16:1532–1543.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Hutt AJ,
    2. Fournell S,
    3. Caldwell J
    (1986) Application of a radial compression column to the high-performance liquid chromatographic separation of the enantiomers of some aryl-propionic acids as their diastereoisomeric. S-(−)-1-(naphthen-1-yl)ethylamides. J Chromatogr 378:409–418.
    OpenUrlPubMed
  7. ↵
    1. Isaacs NS
    (1987a) Physical Organic Chemistry (Longman Scientific & Technical, Harlow, Essex), pp 331–353.
  8. ↵
    1. Isaacs NS
    (1987b) Physical Organic Chemistry (Longman Scientific & Technical, Harlow, Essex), pp 171–209.
  9. ↵
    1. Kawazoe Y,
    2. Ohnishi M
    (1964) Quantitative analysis of active hydrogen by nuclear magnetic resonance. Chem Pharm Bull 11:846–848.
    OpenUrl
  10. ↵
    1. Knihinicki RD,
    2. William KM,
    3. Day RO
    (1989) Chiral inversion of 2-arylpropionic acid non steroidal anti-inflammatory drugs. I. In vitro studies of ibuprofen and flurbiprofen. Biochem Pharmacol 38:4389–4395.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Mayer JM
    (1990) Stereoselective metabolism of antiinflammatory 2-aryl-propionates. Acta Pharm Nord 2:197–216.
    OpenUrlPubMed
  12. ↵
    1. Mayer JM,
    2. Roy-de Vos M,
    3. Audergon C,
    4. Testa B,
    5. Etter JC
    (1994) Interactions of antiinflammatory 2-arylpropionates (profens) with the metabolism of fatty acids: In vitro studies. Int J Tissue React XVI:59–72.
    OpenUrl
  13. ↵
    1. Necciari J,
    2. Donat F,
    3. Gaud C,
    4. Pinchart MC,
    5. Strauch G,
    6. Berger Y
    (1996) Clopidogrel: Assessment of dose proportionality of the carboxylic acid metabolite of clopidogrel. ISSX Proceedings (International Society for the Study of Xenobiotics, Bethesda, MD), 10:384.
  14. ↵
    1. Reist M,
    2. Carrupt PA,
    3. Testa B,
    4. Lehmann S,
    5. Hansen JJ
    (1996) Kinetics and mechanisms of racemization: 5-Substituted hydantoins (=imidazolidine-2,4-diones) as models of chiral drugs. Helv Chim Acta 79:767–778.
    OpenUrl
  15. ↵
    1. Reist M,
    2. Christiansen LH,
    3. Christoffersen P,
    4. Carrupt PA,
    5. Testa B
    (1995) Low configurational stability of amfepramone and cathinone: Mechanism and kinetics of chiral inversion. Chirality 7:469–473.
    OpenUrl
  16. ↵
    1. Reist M,
    2. Testa B,
    3. Carrupt PA
    (1997) The racemization of enantiopure drugs: Helping medicinal chemists to approach the problem. Enantiomer 2:147–155.
    OpenUrl
  17. ↵
    1. Roy-de Vos M,
    2. Mayer JM,
    3. Etter JC,
    4. Testa B
    (1996) Clofibric acid increases the unidirectional chiral inversion of ibuprofen in rat liver preparations. Xenobiotica 26:571–582.
    OpenUrlPubMed
  18. ↵
    1. Savi P,
    2. Combalbert J,
    3. Gaich C,
    4. Rouchon MC,
    5. Maffrand JP,
    6. Berger Y,
    7. Herbert JM
    (1994) The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450–1A. Thromb Haemostasis 72:313–317.
    OpenUrlPubMed
  19. ↵
    1. Savi P,
    2. Herbert JM,
    3. Pflieger AM,
    4. Dol F,
    5. Delbassee D,
    6. Combalbert J,
    7. Defreyn G,
    8. Maffrand JP
    (1992) Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 44:527–532.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Seglen PO
    (1975) Preparation of isolated rat liver cells. Methods Cell Biol 13:29–83.
    OpenUrl
  21. ↵
    1. Testa B
    (1973) Some chemical and stereochemical aspects of diethylpropion metabolism in man. Acta Pharm Suec 10:441–454.
    OpenUrlPubMed
  22. ↵
    1. Testa B,
    2. Carrupt PA,
    3. Gal J
    (1993) The so-called “interconversion” of stereoisomeric drugs: An attempt at clarification. Chirality 5:105–111.
    OpenUrlPubMed
  23. ↵
    1. Yeh C
    (1990) Estimation and significant tests of area under the curve derived from incomplete blood sampling. Biopharmaceutical Section of the Proceedings of the Annual Meeting of the American Statistical Association, Anaheim, CA: ASA; pp 74–81..
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 28 (12)
Drug Metabolism and Disposition
Vol. 28, Issue 12
1 Dec 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Very Slow Chiral Inversion of Clopidogrel in Rats: A Pharmacokinetic and Mechanistic Investigation
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Very Slow Chiral Inversion of Clopidogrel in Rats: A Pharmacokinetic and Mechanistic Investigation

Marianne Reist, Marieke Roy-de Vos, Jean-Pierre Montseny, Joachim M. Mayer, Pierre-Alain Carrupt, Yves Berger and Bernard Testa
Drug Metabolism and Disposition December 1, 2000, 28 (12) 1405-1410;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Very Slow Chiral Inversion of Clopidogrel in Rats: A Pharmacokinetic and Mechanistic Investigation

Marianne Reist, Marieke Roy-de Vos, Jean-Pierre Montseny, Joachim M. Mayer, Pierre-Alain Carrupt, Yves Berger and Bernard Testa
Drug Metabolism and Disposition December 1, 2000, 28 (12) 1405-1410;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • In Vivo Functional Effects of CYP2C9 M1L
  • Clearance pathways: fevipiprant with probenecid perpetrator
  • Predicting Volume of Distribution from In Vitro Parameters
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics